Trends in Hospitalization Expenditures for Acute Exacerbations of COPD in Beijing from 2009 to 2017

References

• KadelR. GBD 2017 causes of death collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• ZhouM, WangH, ZengX, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-131248666
   PubMed Web of Science ®Google Scholar
• ZhongN, WangC, YaoW, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760. doi:10.1164/rccm.200612-1749OC17575095
   PubMed Web of Science ®Google Scholar
• WangC, XuJ, YangL, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-929650248
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• ViniolC, VogelmeierCF. Exacerbations of COPD. Eur Respir Rev. 2018;27(147):170103. doi:10.1183/16000617.0103-201729540496
   PubMed Web of Science ®Google Scholar
• MiravitllesM, García-PoloC, DomenechA, VillegasG, CongetF, de la RozaC. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013;191(5):523–530. doi:10.1007/s00408-013-9487-z23842641
   PubMed Web of Science ®Google Scholar
• DalalAA, ChristensenL, LiuF, RiedelAA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–349. doi:10.2147/COPD.S1377121037958
   PubMedGoogle Scholar
• StafylaE, GeitonaM, KerenidiT, EconomouA, DaniilZ, GourgoulianisKI. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis. 2018;13:309–315. doi:10.2147/COPD.S14805129398912
   PubMed Web of Science ®Google Scholar
• LisspersK, LarssonK, JohanssonG, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis. 2018;13:275–285. doi:10.2147/COPD.S14963329391785
   PubMed Web of Science ®Google Scholar
• HuberMB, WackerME, VogelmeierCF, LeidlR. Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS One. 2015;10(4):e0123292. doi:10.1371/journal.pone.012329225875204
   PubMed Web of Science ®Google Scholar
• ManninoDM, HiguchiK, YuTC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–150. doi:10.1378/chest.14-243425675282
   PubMed Web of Science ®Google Scholar
• GerdthamUG, AnderssonLF, EricssonA, et al. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort. Eur J Health Econ. 2009;10(2):217–226. doi:10.1007/s10198-008-0121-618853206
   PubMed Web of Science ®Google Scholar
• LiM, WangF, ChenR, et al. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. Int J Chron Obstruct Pulmon Dis. 2018;13:3349–3357. doi:10.2147/COPD.S17514330349238
   PubMed Web of Science ®Google Scholar
• ChenX, WangN, ChenY, XiaoT, FuC, XuB. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–2632. doi:10.2147/COPD.S11852327799761
   PubMed Web of Science ®Google Scholar
• OrnekT, TorM, AltınR, et al. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 2012;9(4):285–290. doi:10.7150/ijms.403922701335
   PubMed Web of Science ®Google Scholar
• Dal NegroRW, BonadimanL, TurcoP, TognellaS, IannazzoS. Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update. Clinicoecon Outcomes Res. 2015;7:153–159. doi:10.2147/CEOR.S7750425834458
   PubMedGoogle Scholar
• Chinese Expert Group on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (revised edition in 2014). Int J Respir. 2014;34:1–11. Chinese.
   Google Scholar
• COPD Group of Chinese Society of Respiratory Disease. Guideline for diagnosis and treatment of chronic obstructive pulmonary disease (revised edition in 2013). Chin J Fron Med Sci. 2013;6(2):67–80. Chinese
   Google Scholar
• JinjuvadiaC, JinjuvadiaR, MandapakalaC, DurairajanN, LiangpunsakulS, SoubaniAO. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD. 2017;14(1):72–79. doi:10.1080/15412555.2016.119966927419254
   PubMedGoogle Scholar
• National Center for Health Statistics (NCHS). Diseases of the respiratory system (J00-J99). In: national center for health statistics (NCHS), ed. ICD-10-CM official guidelines for coding and reporting FY 2020. Available from: https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2020_final.pdf. Accessed 824, 2019.
   Google Scholar
• SouliotisK, KousoulakouH, HillasG, TzanakisN, ToumbisM, VassilakopoulosT. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395–1400. doi:10.2147/COPD.S13282528546747
   PubMed Web of Science ®Google Scholar
• ChenZ. Launch of the health-care reform plan in China. Lancet. 2009;373(9672):1322–1324. doi:10.1016/S0140-6736(09)60753-419376436
   PubMed Web of Science ®Google Scholar
• PereraPN, ArmstrongEP, SherrillDL, SkrepnekGH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141. doi:10.3109/15412555.2011.65023922409371
   PubMedGoogle Scholar
• DenizS, SengulA, AydemirY, Celdir EmreJ, ÖzhanMH. Clinical factors and comorbidities affecting the cost of hospital-treated COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3023–3030. doi:10.2147/COPD.S12063727980399
   PubMed Web of Science ®Google Scholar
• TorabipourA, HakimA, Ahmadi AngaliK, DolatshahM, YusofzadehM. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: a state-level cross-sectional study. Tanaffos. 2016;15(2):75–82.27904538
   PubMedGoogle Scholar
• LiuH, WangN, ChenW, et al. Hospitalization trends in adult patients with COPD and other respiratory diseases in northeast China from 2005 to 2015. Biomed Res Int. 2018;2018:1–7.
   Web of Science ®Google Scholar
• de Miguel-díezJ, Jiménez-GarcíaR, Hernández-BarreraV, et al. Trends in hospital admissions for acute exacerbation of COPD in Spain from 2006 to 2010. Respir Med. 2013;107(5):717–723. doi:10.1016/j.rmed.2013.01.00723421969
   PubMed Web of Science ®Google Scholar
• YipWC, HsiaoWC, ChenW, HuS, MaJ, MaynardA. Early appraisal of China’s huge and complex health‐care reforms. Lancet. 2012;379(9818):833–842. doi:10.1016/S0140-6736(11)61880-122386036
   PubMed Web of Science ®Google Scholar